Teva Pharmaceutical Industries Limited American Depositary Shares insider trading
TEVAfinancial statementsForm 4 filings on EDGAR190 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Teva Pharmaceutical Industries Limited American Depositary Shares bought $0 of stock in the open market, and 6 sold $16M. Officers and directors accounted for $0 of purchases and $16M of sales. The last reported transaction was an option exercise by Savage Brian on September 18, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through September 22, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $16MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
190 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | option exercise | 4,503 | $34.70 | $156K | 15,842 | Sep 22, 2026 |
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | open-market sale | 4,503 | $38.69 | $174K | 11,339 | Sep 22, 2026 |
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | open-market sale | 2,525 | $39.15 | $99K | 8,814 | Sep 22, 2026 |
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | open-market sale | 314 | $38.70 | $12K | 8,500 | Sep 22, 2026 |
| Sep 18, 2026 | Mignone Roberto | Director | open-market saleindirect | 367,600 | $39.06 | $14M | 0 | Sep 22, 2026 |
| Aug 21, 2026 | Weiss Amir | Chief Accounting Officer | open-market sale | 6,945 | $37.61 | $261K | 13,071 | Aug 25, 2026 |
| Aug 21, 2026 | Weiss Amir | Chief Accounting Officer | option exercise | 2,500 | $19.61 | $49K | 15,571 | Aug 25, 2026 |
| Aug 21, 2026 | Weiss Amir | Chief Accounting Officer | open-market sale | 2,500 | $37.63 | $94K | 13,071 | Aug 25, 2026 |
| Aug 21, 2026 | Satchi-Fainaro Ronit | Director | open-market sale | 415 | $37.25 | $15K | 111,986 | Aug 25, 2026 |
| Aug 17, 2026 | Lippman Evan | EVP, Business Development | open-market sale10b5-1 | 18,600 | $36.57 | $680K | 25,591 | Aug 19, 2026 |
| Aug 5, 2026 | Zaks Tal Zvi | Director | open-market sale | 17 | $34.87 | $593 | 73,247 | Aug 10, 2026 |
| Aug 3, 2026 | Jover Placid | See "Remarks" | option exercise | 12,827 | — | — | 19,601 | Aug 5, 2026 |
| Aug 3, 2026 | Jover Placid | See "Remarks" | open-market sale10b5-1 | 12,827 | $34.88 | $447K | 6,774 | Aug 5, 2026 |
| Aug 3, 2026 | Hughes Eric A | See "Remarks" | option exercise | 52,744 | — | — | 160,455 | Aug 5, 2026 |
| Aug 3, 2026 | Hughes Eric A | See "Remarks" | open-market sale10b5-1 | 25,578 | $34.88 | $892K | 134,877 | Aug 5, 2026 |
| Jun 18, 2026 | Shields Matthew | EVP, Global Operations | open-market sale | 9,989 | $32.19 | $322K | 0 | Jun 22, 2026 |
| Jun 11, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | open-market sale10b5-1 | 106,563 | $34.10 | $4M | 65,621 | Jun 16, 2026 |
| Jun 5, 2026 | Barer Sol J | Director | option exercise | 21,739 | — | — | 448,011 | Jun 8, 2026 |
| Jun 5, 2026 | Lichtenstein Chen | Director | option exercise | 14,492 | — | — | 19,296 | Jun 8, 2026 |
| Jun 5, 2026 | Crane Rosemary A | Director | option exercise | 14,492 | — | — | 127,739 | Jun 8, 2026 |
| Jun 5, 2026 | Elstein Amir | Director | option exercise | 14,492 | — | — | 2M | Jun 8, 2026 |
| Jun 5, 2026 | Lieberman Gerald M | Director | option exercise | 14,492 | — | — | 130,149 | Jun 8, 2026 |
| Jun 5, 2026 | Nisen Perry | Director | option exercise | 14,492 | — | — | 119,807 | Jun 8, 2026 |
| Jun 5, 2026 | Satchi-Fainaro Ronit | Director | option exercise | 14,492 | — | — | 112,401 | Jun 8, 2026 |
| Jun 5, 2026 | Zaks Tal Zvi | Director | option exercise | 14,492 | — | — | 73,264 | Jun 8, 2026 |
| Jun 5, 2026 | Mignone Roberto | Director | option exercise | 14,492 | — | — | 119,807 | Jun 8, 2026 |
| Jun 5, 2026 | Francis Richard D | President and CEO | option exercise | 13,043 | — | — | 1M | Jun 8, 2026 |
| Jun 5, 2026 | Francis Richard D | President and CEO | open-market sale10b5-1 | 6,153 | $34.35 | $211K | 1M | Jun 8, 2026 |
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | option exercise | 16,195 | — | — | 26,184 | Jun 4, 2026 |
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | open-market sale10b5-1 | 16,195 | $32.87 | $532K | 9,989 | Jun 4, 2026 |
| May 14, 2026 | Lippman Evan | EVP, Business Development | option exercise | 11,841 | — | — | 11,841 | May 18, 2026 |
| May 14, 2026 | Lippman Evan | EVP, Business Development | open-market sale10b5-1 | 5,746 | $35.58 | $204K | 6,095 | May 18, 2026 |
| May 14, 2026 | Lippman Evan | EVP, Business Development | option exercise | 74,008 | — | — | 80,103 | May 18, 2026 |
| May 14, 2026 | Lippman Evan | EVP, Business Development | open-market sale10b5-1 | 35,912 | $35.58 | $1M | 44,191 | May 18, 2026 |
| May 14, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | open-market sale10b5-1 | 153,251 | $35.61 | $5M | 172,184 | May 18, 2026 |
| May 6, 2026 | Weiss Amir | Chief Accounting Officer | open-market sale | 10,679 | $36.00 | $384K | 20,016 | May 7, 2026 |
| May 5, 2026 | Daniell Richard | EVP, Europe Commercial | open-market sale | 30,000 | $35.40 | $1M | 55,755 | May 7, 2026 |
| May 1, 2026 | Sabag Mark | See "Remarks" | open-market sale | 144,180 | $34.99 | $5M | 80,760 | May 4, 2026 |
| Apr 30, 2026 | Fox Christine | EVP, U.S. Commercial | open-market sale | 21,258 | $35.31 | $751K | 63,647 | May 4, 2026 |
| Mar 17, 2026 | Sabag Mark | "See ""Remarks""" | open-market sale | 62,102 | $30.14 | $2M | 224,940 | Mar 19, 2026 |
| Mar 5, 2026 | Sabag Mark | "See ""Remarks""" | option exercise | 15,723 | — | — | 287,042 | Mar 9, 2026 |
| Mar 5, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | option exercise | 19,916 | — | — | 325,435 | Mar 9, 2026 |
| Mar 5, 2026 | Weiss Amir | Chief Accounting Officer | option exercise | 3,537 | — | — | 30,695 | Mar 9, 2026 |
| Mar 5, 2026 | Francis Richard D | President and CEO | option exercise | 42,452 | — | — | 1M | Mar 9, 2026 |
| Mar 5, 2026 | Francis Richard D | President and CEO | open-market sale10b5-1 | 20,025 | $31.67 | $634K | 1M | Mar 9, 2026 |
| Mar 5, 2026 | Fox Christine | EVP, U.S. Commercial | open-market sale10b5-1 | 7,924 | $31.67 | $251K | 84,905 | Mar 9, 2026 |
| Mar 5, 2026 | Fox Christine | EVP, U.S. Commercial | option exercise | 17,819 | — | — | 92,829 | Mar 9, 2026 |
| Mar 5, 2026 | Hughes Eric A | "See ""Remarks""" | option exercise | 19,654 | — | — | 117,244 | Mar 9, 2026 |
| Mar 5, 2026 | Hughes Eric A | "See ""Remarks""" | open-market sale10b5-1 | 9,533 | $31.67 | $302K | 107,711 | Mar 9, 2026 |
| Mar 5, 2026 | Daniell Richard | EVP, Europe Commercial | open-market sale10b5-1 | 17,295 | $31.67 | $548K | 85,755 | Mar 9, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Francis Richard D | President and CEO | Jun 5, 2026 | option exercise | 1M | — | $31M (7) | 7 of 7 |
| Mignone Roberto | Director | Sep 18, 2026 | open-market sale | 119,807 | — | $23M (4) | 0 of 4 |
| Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Jun 11, 2026 | open-market sale | 65,621 | — | $21M (3) | 3 of 3 |
| Sabag Mark | See "Remarks" | May 1, 2026 | open-market sale | 80,760 | — | $13M (4) | 0 of 4 |
| Daniell Richard | EVP, Europe Commercial | May 5, 2026 | open-market sale | 55,755 | — | $12M (8) | 6 of 8 |
| Hughes Eric A | See "Remarks" | Aug 3, 2026 | option exercise | 160,455 | — | $4M (5) | 5 of 5 |
| Fox Christine | EVP, U.S. Commercial | Apr 30, 2026 | open-market sale | 63,647 | — | $3M (5) | 3 of 5 |
| Lippman Evan | EVP, Business Development | Aug 17, 2026 | open-market sale | 25,591 | — | $2M (3) | 3 of 3 |
| Weiss Amir | Chief Accounting Officer | Aug 21, 2026 | open-market sale | 13,071 | — | $1M (5) | 0 of 5 |
| Shields Matthew | EVP, Global Operations | Jun 18, 2026 | open-market sale | 0 | — | $1M (3) | 2 of 3 |
| Jover Placid | See "Remarks" | Aug 3, 2026 | option exercise | 19,601 | — | $895K (2) | 2 of 2 |
| Savage Brian | Interim Chief Legal Officer | Sep 18, 2026 | option exercise | 15,842 | — | $449K (7) | 0 of 7 |
| Satchi-Fainaro Ronit | Director | Aug 21, 2026 | open-market sale | 111,986 | — | $15K (1) | 0 of 1 |
| Zaks Tal Zvi | Director | Aug 5, 2026 | open-market sale | 73,247 | — | $593 (1) | 0 of 1 |
| McAvoy David R. | EVP, Chief Legal Officer | Sep 5, 2025 | open-market buy | 13,027 | — | — | — |
| Barer Sol J | Director | Jun 5, 2026 | option exercise | 448,011 | — | — | — |
| Lichtenstein Chen | Director | Jun 5, 2026 | option exercise | 19,296 | — | — | — |
| Crane Rosemary A | Director | Jun 5, 2026 | option exercise | 127,739 | — | — | — |
| Elstein Amir | Director | Jun 5, 2026 | option exercise | 2M | — | — | — |
| Lieberman Gerald M | Director | Jun 5, 2026 | option exercise | 130,149 | — | — | — |
| Nisen Perry | Director | Jun 5, 2026 | option exercise | 119,807 | — | — | — |
| Vergis Janet S. | Director | Jun 6, 2025 | option exercise | 73,697 | — | — | — |
| Shalev Varda | Director | Jun 6, 2025 | option exercise | 22,504 | — | — | — |
Questions
Are Teva Pharmaceutical Industries Limited American Depositary Shares insiders buying or selling?
Over the twelve months to November 1, 2026, 14 insiders at Teva Pharmaceutical Industries Limited American Depositary Shares sold $113M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $113M. Only open-market purchases and sales are counted.
Who sold the most Teva Pharmaceutical Industries Limited American Depositary Shares stock in the last year?
Francis Richard D (President and CEO) sold $31M in 7 open-market sales over the twelve months to November 1, 2026.
Do Teva Pharmaceutical Industries Limited American Depositary Shares executives sell under 10b5-1 plans?
31 of the 58 open-market sales in the last twelve months (53%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Teva Pharmaceutical Industries Limited American Depositary Shares
- Teva Pharmaceutical Industries Limited American Depositary Shares financial statements
- 3 tracked funds holding TEVA
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.